AACR 2021 | DFIR CAR T-cell therapy for clear cell RCC

Yufei Wang, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the development of dual-targeted fine-tuned immune restoring (DFIR) chimeric antigen receptor (CAR) T-cells for the treatment of clear cell renal cell carcinoma (ccRCC) at AACR 2021. Whilst CAR T-cells have demonstrated efficacy in hematological malignancies, they have not yet shown the same results in solid tumors due to the immunosuppressive tumor microenvironment and other factors. Dr Wang describes how DFIR-CAR T-cells may offer a solution and summarizes existing research in mouse models. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.